MetaCap

Kiniksa Pharmaceuticals International (KNSA) vs Summit Therapeutics (SMMT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kiniksa Pharmaceuticals International (KNSA) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 125.8% versus a loss of 38.5%. Over five years, KNSA leads with a +706.0% price change compared with +92.8% for SMMT. Summit Therapeutics is the larger company by market cap ($7.96 billion vs $7.38 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KNSA+125.82%SMMT-38.54%
+146%+49%-47%
Nov 21, 20251 yearNov 20, 2026
KNSA+669.63%SMMT+85.98%
+728%+302%-124%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KNSA versus SMMT key metrics
MetricKNSASMMT
Share price$93.90$9.95
Market cap$7.38B$7.96B
1-day change+0.38%-5.87%
YTD return+127.62%-43.11%
1-year return+125.82%-38.54%
5-year return+705.97%+92.83%
P/E ratio (TTM)71.13—
Forward P/E45.91—
EPS (TTM)$1.32$-1.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$677.56M—
Revenue growth (YoY)+60.09%—
Net income (latest FY)$59.01M$-1.08B
Gross margin88.54%—
Operating margin11.40%—
Net margin8.71%—
52-week high$99.31$29.23
52-week low$37.02$9.89
Distance from 52-week high-5.45%-65.96%
Analyst consensusstrong_buybuy
Avg. price target upside+18.82%+189.15%
Average volume664.53K6.68M
Shares outstanding48.84M799.76M
Employees366265
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KNSA has outperformed SMMT by 164.4 percentage points over the past year.

About Kiniksa Pharmaceuticals International

KNSA stock →

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees

About Summit Therapeutics

SMMT stock →

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).

Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees

KNSA vs SMMT FAQ

Which is bigger, Kiniksa Pharmaceuticals International or Summit Therapeutics?

Summit Therapeutics (SMMT) is larger, with a market capitalization of $7.96B compared with $7.38B for Kiniksa Pharmaceuticals International (KNSA).

Which stock has performed better over the past year, KNSA or SMMT?

KNSA returned +125.82% over the past 12 months, compared with -38.54% for SMMT (price return, excluding dividends). Past performance does not predict future results.

Are Kiniksa Pharmaceuticals International and Summit Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons